Skip to Content Facebook Feature Image

Papablic Launches SafeguardPlus™ Baby Bottle Washer, the World's First with built-in Water Purification to Remove Lead and Soften Water

Business

Papablic Launches SafeguardPlus™ Baby Bottle Washer, the World's First with built-in Water Purification to Remove Lead and Soften Water
Business

Business

Papablic Launches SafeguardPlus™ Baby Bottle Washer, the World's First with built-in Water Purification to Remove Lead and Soften Water

2026-01-29 20:19 Last Updated At:20:35

NEW YORK, Jan. 29, 2026 /PRNewswire/ -- Papablic, a brand trusted by over 4.5 million parents worldwide, announced the launch of the SafeguardPlus™ Baby Feeding Essentials Cleaning System, the industry's first and only feeding cleaning system with a built-in water purification system designed to remove lead and soften tap water before cleaning begins.

Innovate to Set a Higher Bar on Baby Feeding Hygiene and Safety

The Papablic SafeguardPlus™ Cleaning System marks a major breakthrough in baby feeding hygiene and safety. Unlike conventional solutions that rely on untreated tap water, Papablic's newest innovation addresses an often-overlooked risk in baby feeding: water quality itself.

Parents do everything right to keep baby feeding clean. However, analysis of the U.S. Environmental Protection Agency (EPA) lead testing data shows that systems serving about 81% of the U.S. population have detected lead at or above 1 part per billion (the American Academy of Pediatrics' recommended level for children), and 23.5% of systems have recorded health-based lead violations.

Lead exposure is particularly harmful to infants and children under six because their developing bodies are highly sensitive. Even low levels of lead exposure can cause slowed growth and development mentally and physically.

Papablic SafeguardPlus™ Cleaning System removes avoidable risks at the source by purifying water before cleaning begins.

Deep Clean—From What You See to What You Can't.

With its pioneering PurifyClean™ Technology, Papablic is redefining what "deep clean" truly means—eliminating visible milk residues and invisible harmful contaminants like lead. Unlike traditional solutions that focus on mechanical cleaning alone, SafeguardPlus™ is designed as a complete feeding hygiene system— addresses both visible and invisible risks from the very first step.

"For SafeguardPlus™ Cleaning System, we didn't just optimize the cleaning performance—we addressed the part that no one else was controlling : the water itself," said a Papablic spokesperson. "Our goal is simple -- to do it right and take no risks when it comes to baby feeding safety and health. That's how we safeguard babies and support parents in feeding with greater confidence and ease, by knowing every step is safer by design."

Key Benefits of Papablic SafeguardPlus™ Cleaning System:

  • Built-in Water Purification System: Removes pontentially harmful contaminants such as lead and softens water within one minute for safer, residue-free cleaning. No distilled or bottled water needed.
  • 8-Bottle Capacity: Cleans up to 8 bottles and other feeding accessories in a single cycle, designed for the multiple daily feeds of newborn and multi-child families.
  • 360° Deep Clean with Faster Cycle: A 5-in-1 automated system that filters, washes, sterilizes, dries, and stores feeding essentials, reducing daily cleaning time up to 30% compared with other solutions.
  • Helps Reduce Up to 99.999% Harmful Germs: Reduce harmful germs and prevent cross-infection while remaining safe for feeding essentials.
  • 100% Baby Safe: Made with certified baby-safe, BPA-free materials.

With the launch of SafeguardPlus™ Cleaning System, Papablic establishes a new benchmark in baby feeding hygiene and safety—where real deep clean starts with safer water, safeguarding every feed from the very first sip.

About Papablic

Founded in 2017, Papablic was born from a vision to create better possibilities for modern parenting. Since day one, Papablic has been dedicated to developing innovative and reliable products that support every parent in their daily feeding routines. Known for its best-selling sterilizer and bottle washer, Papablic prioritizes safety and delivers reliable solutions designed to help parents reclaim time, confidence, and freedom. Loved by over 4.5 million families, Papablic's parent-centric products have been featured in popular media outlets such as Babylist, The Bump, and Parents. Originally founded by a papa, Papablic aims to help all parents and caregivers enjoy better parenthood with safer and simpler solutions.

For more information, visit https://papablic.com.

New Launch Event Page:https://papablic.com/products/papablic-safeguardplus%E2%84%A2-baby-bottle-washer-system

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Papablic Launches SafeguardPlus™ Baby Bottle Washer, the World's First with built-in Water Purification to Remove Lead and Soften Water

Papablic Launches SafeguardPlus™ Baby Bottle Washer, the World's First with built-in Water Purification to Remove Lead and Soften Water

BOAO, China, Jan. 29, 2026 /PRNewswire/ -- The International NUT Carcinoma Diagnosis and Treatment Center has been inaugurated at Boao International Hospital. Established through a collaboration between Boao International Hospital and Chongqing University Three Gorges Hospital, this center tackles the profound challenges of NUT carcinoma, a rare cancer known for diagnostic difficulty, limited treatments, and poor survival. The center is powered by a landmark Chinese breakthrough: NHWD-870, a novel, oral BET inhibitor, developed by biotech Zhejiang Wenda Pharma Technology Co., Ltd. Clinical data is promising, showing an objective response rate of 33.3% and a disease control rate of 73.33%. The drug has extended median overall survival to 9.3 months in trials, with real-world studies reporting a one-year survival rate of 54.7%.[1]

"Our mission is to light a definitive beacon of hope," said Professor YIN Mingzhu, a key leader of the center. "We are here to ensure every patient has access to advanced, life-extending care."

Strategically located within the Boao Hope Pilot Zone of International Medical Tourism, the center leverages the zone's unique "Four Special Permissions" policy. This accelerates the introduction of global innovations and fast-tracks domestic breakthroughs like NHWD-870 to clinical use. Alongside a concurrently launched research and innovation platform, the center will function as a global hub for cutting-edge trials, generating evidence to shape future global treatment standards.

The initiative builds on a strong foundation. Chongqing University Three Gorges Hospital is a national pioneer, having established China's first dedicated NUT carcinoma clinic, treated over 200 patients nationwide, and led the development of the nation's first expert consensus on the disease. By combining this deep clinical expertise with Boao's policy advantages, the center aims to create a new model for rare disease care and change the narrative for NUT carcinoma.

International NUT Carcinoma Registry: http://resource.yin-lab.com/NUT/ 

About the Boao Hope Pilot Zone of International Medical Tourism:

Located in Hainan Province, this specially designated zone permits the accelerated clinical use of internationally approved medical products and technologies within China. Having already introduced over 540 innovative therapies, it serves as a vital gateway for medical innovation and international exchange, driving the future of healthcare.

About Zhejiang Wenda

Founded in 2013, Zhejiang Wenda Pharma Technology Co., Ltd. is an innovative drug research and development company committed to pioneering, innovative, and high-quality discoveries. The company strategically focuses on oncology, immunology, and neurodegenerative diseases. It currently has multiple drug candidates advancing through Phase I, II, and III clinical trials.

NHWD-870 is the world's first and only BET inhibitor targeting advanced NUT carcinoma. Having completed Phase II clinical trials, the data has demonstrated excellent safety and efficacy. NUT carcinoma is a rare and aggressive malignant tumor characterized by rapid progression and poor prognosis, with a median age of onset typically between 18 and 23 years.

The company's pipeline also includes peripheral TYK2 (JH2) inhibitor for moderate-to-severe plaque psoriasis currently in Phase III trials, and central TYK2 (JH2) inhibitor for CNS diseases in Phase I trials. With a rich and innovative pipeline targeting numerous current refractory and incurable diseases, the company is dedicated to providing patients with more effective, safer, and cost-efficient innovative therapeutic options.

For more information, please visit: www.wendapharma.com
Contact: BD@wendapharma.com 

[1] 中国食品药品企业质量安全促进会 - 协会动态

[1] 中国食品药品企业质量安全促进会 - 协会动态

 

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Hope Rising in Hainan: International NUT Carcinoma Center Launches in Boao

Hope Rising in Hainan: International NUT Carcinoma Center Launches in Boao

Recommended Articles